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The current study was to prepare a mouse-derived antibody against the angiotensin II type 1 receptor (AT1-mAb) based on
monoclonal antibody technology, to provide a foundation for research on AT1-AA-positive diseases. Balb/C mice were actively
immunized with the second extracellular loop of the angiotensin II type 1 receptor (AT
1
R-ECII). Then, mouse spleen lymphocytes
were fused with myeloma cells and monoclonal hybridomas that secreted AT1-mAb were generated and cultured, after which
those in logarithmic-phase were injected into the abdominal cavity of mice to retrieve the ascites. Highly purified AT1-mAb was
isolated frommouse ascites after injection with 1 × 107 hybridomas. A greater amount of AT1-mAb was purified frommouse ascites
compared to the cell supernatant of hybridomas. AT1-mAb purified from mouse ascites constricted the thoracic aorta of mice and
increased the beat frequency of neonatal ratmyocardial cells via theAT
1
R, identical to the effects of AT1-AA extracted frompatients’
sera. Murine blood pressure increased after intravenous injection of AT1-mAb via the tail vein. High purity and good biological
activity of AT1-mAb can be obtained from mouse ascites after intraperitoneal injection of monoclonal hybridomas that secrete
AT1-mAb. These data provide a simple tool for studying AT1-AA-positive diseases.
1. Introduction
Angiotensin II (Ang II) receptors are a class of G-protein-
coupled receptors that exist in four subtypes: AT
1
R–AT
4
R.
The angiotensin II type 1 receptor (AT
1
R) is mainly expressed
in vascular smooth muscle cells (VSMCs), endothelial cells,
and myocardial fibroblasts [1] and as such plays a prominent
role in regulating the cardiovascular system. Ang II can acti-
vate the AT
1
R, thereby increasing vascular tension, causing
vasoconstriction, and increasing the force of cardiac mus-
cular contractions. However, excessive activation of AT
1
R
can cause cardiovascular pathologies such as hypertension
[2], vascular injury [3], arrhythmia [4], and myocardial
hypertrophy [5].
Preeclampsia is a serious type of pregnancy-induced
hypertension that clinically manifests itself in the form
of high blood pressure and proteinuria after 20 weeks of
pregnancy. Numerous studies have reported that excessive
AT
1
R activation is an important mechanism underlying the
occurrence and development of preeclampsia. Angiotensin
II 1 type autoantibodies (AT1-AA) are agonists of AT
1
R
that can cause excessive activation [6] by interacting with
the second extracellular loop of the AT
1
R (AT
1
R-ECII)
[7], thereby causing high blood pressure and proteinuria,
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which are the typical signs and symptoms of preeclampsia
in pregnant rats. These findings suggest that AT1-AA may
play an important role in the pathology of preeclampsia
[8]. Therefore, evaluating the functions of AT1-AA and its
underlying mechanisms and targets has become a major
research focus. However, obtaining enough highly purified
AT1-AA to establish animal models has been a considerable
problem, as to date only limited amounts of antisera from
clinical patients with preeclampsia have been isolated. To
study the pathophysiological roles of AT1-AA, it is important
to establish a more simple and productive method for the
preparation of these autoantibodies.
In the present study, we prepared a mouse-derived anti-
body against the AT
1
R-ECII (AT1-mAb) using monoclonal
antibody technology.Then, we identified the biological activ-
ities of AT1-mAb and compared them to AT1-AA purified
from preeclamptic patients. This research is aim to find a
simple and effective way to gain AT1-mAb to study AT1-AA
positive disease, so as to provide basis for clinical treatment.
2. Materials and Methods
2.1. Experimental Animals and Materials. Our experiments
were approved by the Institutional Animal Care and Use
Committee of Capital Medical University (Beijing, China)
and conformed to the Guiding Principles in the Use and Care
of Animals published by the National Institutes of Health
(NIHPublication number 85-23, revised 1996). Animals were
provided by Vital River, License: SCXK (Beijing), 2012-0001.
Before the experiments, the mice were fed ad libitum and
maintained in 12-hour light/dark cycles. Healthy, 12-week-
old Balb/C mice (𝑛 = 60; 45 females, 15 males; body weight,
18–20 g) were used for preparation of ascites (vehicle group:
𝑛 = 10, hybridomas (107) group: 𝑛 = 10, females), isolated
vascular ring experiment (𝑛 = 20; 15 females, 5 males), and
experiments in vivo (𝑛 = 20; 10 females, 10 males), and
0–3-day-old newborn Wistar rats (𝑛 = 30; weight, 4–6 g)
were used for neonatal rat cardiomyocytes beat frequency
experiment. We observed these rats at least twice daily.
They were given pentobarbital sodium (150mg/kg) [9] by
intraperitoneal injection (IP) to reduce anxiety for surgical
anesthesia. Once the experiment was completed, all Balb/C
mice were euthanized by decapitation at the guillotine (a
physical method was suggested by AVMA Guidelines on
Euthanasia).
2.2. Purification of AT1-AA from Patients’ Sera. Six pree-
clampsia women were recruited from the Taiyuan Central
Hospital (Taiyuan, Shanxi province, China) (Table 1). This
investigation was conducted according to the principles
expressed in the Declaration of Helsinki.This research proto-
col was approved by the Ethics Committee for the Protection
of Human Subjects of Taiyuan Central Hospital. All patients
had given written consent. Before serumwas collected, 10mL
fasting blood samples were collected from these six subjects
through cubital veins and stand at room temperature for 1
hour and then centrifuged at 3000 rpm for 15min. The sera
were isolated and stored at 20∘C for purification of AT1-AA
[10] over Protein G affinity column (Sweden).
Table 1: Clinical data of patients with preeclampsia subjects.
Patients Preeclampsia (𝑛 = 6)
Maternal age (years) 30 (27–34)
Gestational age at sampling (weeks) 37.5 (35–40)
Ethnic background Han
SBP (mmHg) 152 ± 11
DBP (mmHg) 105 ± 6
Proteinuria (mg/day) 478 ± 33.5
SBP, systolic blood pressure; DBP, diastolic blood pressure.
2.3. Hybridoma Preparation. Peptides against the human
AT
1
R-ECII antigen epitope (murine and human AT
1
R-ECII
share 92% homology, Supplementary Figure 1 (see Supple-
mentaryMaterial available online at http://dx.doi.org/10.1155/
2016/1858252)) were synthesized (I-H-R-N-V-F-F-I-E-N-T-
N-I-T-V-C-A-F-H-Y-E-S-Q-N-S-T; GenBank AAB34644.1)
at 98% purity. The peptides coupled to keyhole limpet
hemocyanin (KLH) protein were used as immunogens, and
those coupled to bovine serum albumin (BSA) were used as
the control. This peptide was used as an antigen to immunize
the mice to prepare sera containing high titers of polyclonal
antibodies, and then the cells were fused to generate the
hybridoma cell lines (Beijing B&MBiotechCo., Ltd.). In total,
40 strains ofmonoclonal hybridoma cell lineswere generated,
and the 5 strains that secreted the highest titers ofAT1-mAb in
the cell culture supernatant were identified by Biotin-Avidin
Enzyme-Linked Immunosorbent Assay (BA-ELISA). Specific
hybridomas were frozen in liquid nitrogen until use.
2.4. Hybridoma Culture. (1) For thawing, the hybridomas
were quickly placed in a CryoTube at 37∘C in a constant-
temperature water bath, transferred to 10mL Roswell Park
Memorial Institute (RPMI) 1640 medium (HyClone, China),
and centrifuged at 3000 rpm for 10min at 4∘C after mixing,
after which the supernatant was removed. (2) For culturing,
the cells were grown in RPMI supplemented with 10% fetal
bovine serum (Gibco, USA). After 24 h, the supernatant was
removed and fresh culture medium was added to the cells.
(3) For subculturing, cells in logarithmic growth phase were
cultured for about 3 days until 80–90% confluency, after
which the supernatantwas collected and frozen at−20∘Cuntil
purification.The remaining cells were also collected and used
for ascites preparation. (4) For cryopreservation and storage
of cells, half-adherent cells were centrifuged at 1000 rpm
for 5min. Then, the supernatant was removed and the cells
were cryopreserved in fetal bovine serum : RPMI : dimethyl
sulfoxide (DMSO) at a ratio of 5 : 4 : 1.
2.5. Extraction of AT1-mAb from Hybridoma Culture Super-
natant and Mouse Ascites. (1) Extraction of AT1-mAb
from hybridoma culture supernatant: the proteins in the
hybridoma culture supernatant were concentrated at a ratio
of 5 : 1 and filtered using a 0.45 𝜇m filter, and the IgG of the
hybridoma culture supernatant was purified over a protein
G affinity column. (2) Extraction of AT1-mAb from mouse
ascites: incomplete Freund’s adjuvant (0.02mL/g, Sigma, St.
Louis, MO, USA) was injected into the abdominal cavity of
Journal of Immunology Research 3
all Balb/C mice. Three days later, 1 × 105–1 × 109 hybridomas
suspended in 0.4mL phosphate-buffered saline (PBS) were
introduced into mouse abdominal cavity by IP injection with
a 1mL syringe. Ascites formation was observed by weighed
and abdominal shape at everyweek, ascites fluidwas collected
in the second week, and the supernatant was collected after
centrifugation at 1000 rpm for 5min and diluted in PBS and
affinity purified with immobilized Protein G. And all mice
were euthanized by decapitation at the 4th week, when they
cannot generate much more ascites.
2.6. Specificity Identification of the AT1-mAb. (1)The purified
antibodies were resolved on a 15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel, and
the gel was stained with Coomassie Brilliant Blue. (2) The
specificity of the antibodies purified from the hybridoma
culture supernatant and mouse ascites was determined by
BA-ELISA [11], with thewavelength of detection set at 405 nm
to provide the optical density (OD) (Spectra Max Plus;
Molecular Devices, Sunnyvale, CA): 𝑃/𝑁 = (positive OD
− blank OD)/(negative OD − blank OD); 𝑃/𝑁 > 2.1 was
identified as the positive sample; 𝑃/𝑁 < 1.5 was identified
as the negative sample. The procedure is as follows: 1 𝜇g/mL
AT
1
R-ECII peptide dissolved in Na
2
CO
3
solution (0.1mol/L,
pH 11.0)was coated in 96-wellmicrotiter plates and incubated
overnight at 4∘C. The wells were saturated with 1% PMT
buffer (1% (w/v) bovine serum albumin, 0.1% (v/v) Tween 20
in phosphate-buffered saline (PBS-T), pH 7.4) at 37∘C for 1 h.
After washing the plates with PBS-T for 3 times, 5𝜇L samples
diluted in 45 𝜇L PMT were added to the plates and incubated
at 37∘C for 1.5 h. After 3 times’ washing, biotinylated rabbit
anti-mouse IgG antibodies and biotinylated goat anti-human
IgG antibodies (1 : 4500 dilutions in PMT; Zhong Shan Jin
Qiao, Beijing, China) were added to the wells and incubated
at 37∘C for 1 h. After 3 times’ washing, the streptavidin-
peroxidase conjugate (1 : 3000, Vector, CA) was added to the
wells and incubated at 37∘C for 1 h. Finally, 2,2-azino-di(3-
ethylbenzothiazoline) sulfonic acid- (ABTS-) H
2
O
2
(Roche,
Basel, Switzerland) substrate buffer was applied and reacted
in the dark at 37∘C for 0.5 h.
2.7. The Biological Activity and Functional Identification of
AT1-mAb. (1) For the cultivation of primary neonatal rat
myocardial cells, we rapidly removed hearts from 0–3-day-
old newborn Wistar rats into PBS, cut them into pieces,
and washed away the blood cells for 2-3 times with PBS.
35mg trypsin and 25mg collagenase type II were dissolved in
30mL PBS.These digestive enzymes were filtered by 0.22𝜇m
filters and then stand at 37∘C. The heart tissue was added
into 5mL beaker and digested in 3mL enzyme solution for
3–5min with sustained shaking at 37∘C. The supernatant
was aspirated into low-glucose Dulbecco’s Modified Eagle’s
medium (DMEM) with 10% fetal bovine serum to termi-
nate digestion. Finally, the cells were centrifuged through a
200-mesh filter and centrifuged at 1000 rpm for 5min and
placed in 10 cm dish. After 2 hours, the supernatant was
aspirated and packed in 6-well plates, the adherent cells
were fibroblast cells. After culturing for 5 days, the beat of
the myocardial cells was observed under a microscope. The
AT
1
R blocker valsartan (Sigma, Y0001132) and AT
2
R blocker
PD123319 (Sigma, P186) were added to the myocardial cell
culture medium. After 10 minutes, purified AT1-mAb was
added to the culture medium, and the beat frequency of
the myocardial cells was recorded. (2) For isolated vascular
ring technology [12], the sodium pentobarbital was used
for surgical anesthesia before isolating aortic rings from the
mice.Themicewere euthanized by decapitation after thoracic
aortas were isolated immediately, and a 2mm vascular ring
was removed and affixed to an internal System-610M Multi
Myograph bath sensor (Danish Myo Technology A/S Inc.,
Denmark). The bath contained 5mL hydroxyethyl piper-
azine ethanesulfonic acid 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES; 144mM NaCl, 5.8mM KCl,
1.2mM MgCl
2
N
6
H
2
O, 2.5mM CaCl
2
, 11.1mM glucose, and
5mM HEPES) solution (pH, 7.38–7.40) into which a 95%
O
2
/5% CO
2
gas mixture was continually bubbled. We
allowed a 1 h equilibration period before the start of the
experiment, and the HEPES solution was replaced every
15min. Using the vascular ring transducer system, vascular
ring tension changes were collected and recorded with
LabChart 7 software. The initial passive vascular tension
was determined by vascular standardization. HEPES buffer
containing 60mM potassium (144mM NaCl, 60mM KCl,
1.2mM MgCl
2
N
6
H
2
O, 2.5mM CaCl
2
, 11.1mM glucose, and
5mM HEPES; pH, 7.38–7.40) was used for a precontracted
vasoactive test.The contractile responses of the vascular rings
(tension) to different drugs were defined as a percentage
of average contractile intensity to KCl (KCl% = detected
drugs/ΔKCl × 100%). (3) The tail-cuff method was used to
measure blood pressure in mice, and the position of the
mouse was fixed by using a mouse holder maintained on a
37∘C hot plate, while a small mouse tail blood flow sensor
was placed at the mouse tail root; we then waited until the
heart rate stabilized at approximately 375 beats/min. After
the blood began to flow smoothly and steadily, we measured
systolic blood pressure five times per animal using software
of noninvasive automated sphygmomanometer (Japan) and
recorded the mean overall blood pressure.
2.8. Statistical Analysis. Using SPSS 16.0 (Chicago, IL, USA)
for statistical analysis, between-group comparisons were
performed with 𝑡-tests, and comparisons among groups were
performed with one-way ANOVA, followed by Tukey’s post
hoc test (∗𝑃 < 0.05, ∗∗𝑃 < 0.01). All of the bar graphs are
shown as the mean ± standard error of the mean (SEM).
3. Results
3.1. Concentration of AT1-mAb Is Higher in Mouse Ascites
Than in Hybridoma Supernatant. Hybridoma supernatant
was collected after 3 days of culture. The results of the bicin-
choninic acid (BCA) assay revealed that the concentration
of the monoclonal antibodies purified from the supernatant
was 3.75 × 10−6mol/L. Different amounts of hybridomas were
injected into the abdominal cavity of mice (1 × 105, 1 × 106,
1 × 107, 1 × 108, and 1 × 109), and different concentrations
(2.5 × 10−6, 9.3 × 10−6, 3 × 10−5, 1.32 × 10−5, and 1.49 ×
10−5mol/L) of monoclonal antibodies were obtained. The
4 Journal of Immunology Research
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Figure 1: Concentration of AT1-mAb purified from mouse ascites was higher than that from hybridoma supernatant. (a) Concentration of
monoclonal antibody that was purified from mouse ascites (∗∗𝑃 < 0.01 versus 1 × 10−5, 1 × 10−6, 1 × 10−8, and 1 × 10−9, 𝑛 = 8). (b) Content
of AT1-mAb that was purified from the cellular supernatant of hybridomas compared with that from mouse ascites, and positive control was
the AT1-AA purified from preeclampsia sera. #𝑃 < 0.05 versus cellular supernatant; ∗𝑃 < 0.05 versus control; ∗∗𝑃 < 0.01 versus control. Data
represent the mean ± SEM; 𝑛 = 8.
highest concentration of monoclonal antibodies purified
frommouse ascites was from the group that was injected with
1 × 107 hybridomas (𝑃 < 0.01 versus 1 × 10−5, 1 × 10−6, 1
× 10−8, and 1 × 10−9; 𝑛 = 8) (Figure 1(a)). The BA-ELISA
results showed that the monoclonal antibodies purified from
hybridoma supernatants and mouse ascites were AT1-mAb,
AT1-AA purified from preeclampsia sera was used as positive
control, and the sera from AT1-AA-negative Balb/C mice
were used as control (𝑃/𝑁 values: positive control, 3.96 ± 1.9
versus 0.88 ± 0.43 for controls; 𝑃 < 0.05; hybridoma cell
culture supernatant, 3.11±1.81 versus 0.88±0.43 for controls;
𝑃 < 0.05; mouse ascites, 8.07 ± 3.32 versus 0.88 ± 0.43
for controls; 𝑃 < 0.01; 𝑛 = 8); the content of AT1-mAb
purified from mouse ascites was higher than that purified
from the hybridoma supernatant (𝑃/𝑁: 8.07 ± 3.12 versus
3.11 ± 1.81 for the supernatant; 𝑃 < 0.05; 𝑛 = 8) (Figure 1(b))
and we extracted the whole protein from the neonatal rat
cardiomyocytes, which express the AT
1
R; the Western blot
showed that both AT1-AA and AT1-mAb can recognize AT
1
R
at the same location specifically (Supplementary Figure 2).
3.2. AT1-mAb Purified from Mouse Ascites Belongs to the IgG
Immunoglobulin Class. SDS-PAGE was used to analyze the
purity of hybridoma supernatant and mouse ascites. The
results showed that the antibody extracted from hybridoma
supernatant showed that there were several other bands in
addition to the heavy and light chain (Figure 2(b)); compared
to IgG control (Figure 2(a)), the heavy and light chain of
purified AT1-mAb were 55 kDa and 25 kDa (Figure 2(c)),
which revealed that the antibody extracted from mouse
ascites belongs to the IgG immunoglobulin class.
3.3. AT1-mAb Purified from Mouse Ascites Increases the
Beat Frequency of Newborn Rat Cardiomyocytes. As shown
in Figure 3 (the picture of the newborn rat cardiomy-
ocytes, Figure 3(a)), when 10−8mol/L AT1-mAb (purified
from mouse ascites) was added to the culture medium, the
beat frequency of the newborn rat cardiomyocytes increased,
similar to the effect caused by AT1-AA (10−8mol/L) extracted
frompatients’ sera (AT1-mAb, 77.67±19.67 versus 57.08±5.29
before treatment; AT1-AA, 84.33 ± 8.33 versus 60.67 ± 3.79
before treatment; 𝑃 < 0.05; 𝑛 = 6); Ang II (10−7mol/L), the
endogenous AT
1
R agonist, also increased the beat frequency
of the rat cardiomyocytes (99.71 ± 22.14 versus 58.36 ±
5.75 before treatment; 𝑃 < 0.05; 𝑛 = 6); AT
1
R blocker
valsartan (10−7mol/L) could block the beating frequency
increase caused by AT1-mAb, although the AT
2
R blocker
PD123319 (10−7mol/L) did not have an inhibitory effect
(94.08 ± 2.89 versus 72.03 ± 5.77 before treatment; 𝑃 < 0.05;
𝑛 = 6) (Figure 3(b)). These data reveal that AT1-mAb can
increase the beat frequency of newborn rat cardiomyocytes
by activating the AT
1
R, but not AT
2
R.
3.4. AT1-mAb Purified from Mouse Ascites Induces Contrac-
tion of the Thoracic Aorta. The results in Figure 4 show
that both 10−7mol/L Ang II and 10−8mol/L AT1-mAb
purified from mouse ascites could induce vasoconstriction.
Compared to negative IgG group (Figure 4(a)), the effect
Journal of Immunology Research 5
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Figure 2: Purity of AT1-mAb from hybridoma supernatant and mouse ascites. (a) IgG control; (b) the antibody extracted from hybridoma
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Figure 3: Biological activity of AT1-mAb was identified by changes in beat frequency of neonatal rat myocardial cells. (a) Cultured neonatal
rat myocardial cells. Scale bar = 200 𝜇m. (b) Different processing factors had different effects on beating frequency of cultured neonatal rat
myocardial cells in vitro. ∗𝑃 < 0.05 versus before treating. Data represent the mean ± SEM; 𝑛 = 6.
of AT1-mAb on vascular function was the same as that
caused by AT1-AA (10−8mol/L) extracted from patients’ sera
(tension values: Ang II, Figure 4(b), 52.71% ± 20.86% ver-
sus 3.72% ± 2.26% for negative IgG; AT1-mAb, Figure 4(c),
37.51% ± 16.42%versus 3.72% ± 2.26% for negative IgG;AT1-
AA, Figure 4(f), 40.50% ± 19.20% versus 3.72% ± 2.26% for
negative IgG; 𝑃 < 0.05; 𝑛 = 6). When valsartan (10−7mol/L)
was added first, the vasoconstriction caused by AT1-mAbwas
blocked (Figure 4(d), 𝑃 > 0.05; 𝑛 = 6). However, when
PD123319 (10−7mol/L) was added first, the vasoconstriction
caused by AT1-mAb could not be blocked (Figure 4(e),
28.93% ± 10.04% versus 3.72% ± 2.26% for negative IgG;𝑃 <
0.05; 𝑛 = 6). Statistical graph of isolated vascular ring is
Figure 4(g). These results demonstrate that AT1-mAb exerts
its biological functions by activating the AT
1
R, but not the
AT
2
R.
3.5. AT1-mAbDirectly Increases the Blood Pressure of Pregnant
Mice. Twelve-week-old healthy adult females and males
were caged together, and ultrasonography showed successful
6 Journal of Immunology Research
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Figure 4: Continued.
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Figure 4: Biological activity of AT1-mAb was identified by isolated thoracic aorta ring technology. (a) Negative IgG isolated from healthy
mouse serum; (b) Agonist of AT
1
R, Ang II; (c) AT1-mAb; (d) for AT1-AA exert the same effect on the contractile force of mouse thoracic
aorta; (e) blocking agent for AT
1
R, valsartan; (f) valsartan + AT1-mAb; (g) blocking agent for AT
2
R, PD123319; (h) PD123319 + AT1-mAb;
and (i) statistical graph of isolated vascular ring. ∗𝑃 < 0.05 versus negative IgG. Data represent the mean ± SEM; 𝑛 = 6.
pregnancy. On the 13th day of gestation, AT1-mAb (20𝜇g/g)
[13] was injected into the pregnant mice through the tail
vein, and an equal dose of normal saline was injected into
the mice in the control group (control group, Figure 5(a);
AT1-mAb group, Figure 5(b)). The content of the AT1-mAb
in pregnant mice sera was tested on days 14, 16, and 18 of
gestation. The levels of AT1-mAb began to rise from the 14th
day of gestation and were maintained to the 18th day (OD
on day 14 of gestation: 0.27 ± 0.05 versus 0.12 ± 0.02 for
saline; day 16 of gestation, 0.26 ± 0.05 versus 0.14 ± 0.016
for saline; day 18 of gestation, 0.25 ± 0.03 versus 0.13 ± 0.02
for saline; 𝑃 < 0.05; 𝑛 = 6; Figure 5(c)). On alternate days,
blood pressures were measured using mouse tail sensors.The
systolic blood pressures of AT1-mAb-positive pregnant mice
were significantly higher than those of mice in the control
group on days 14, 16, and 18 of gestation (118.46 ± 5.82 versus
92.94 ± 7.64mmHg for saline on day 14 of gestation: 129.78 ±
8.92 versus 98.08 ± 10.81 for saline on day 16 of gestation;
and 137.69 ± 4.73 versus 97.10 ± 9.17 for saline on day 18 of
gestation; 𝑃 < 0.05; 𝑛 = 6; Figure 5(d)).
4. Discussion
A large number of studies have identified AT1-AA as a
harmful factor that exists in several diseases associated
with cardiovascular disturbances, especially in patients with
preeclampsia [14]. It plays an agonistic role by specifi-
cally interacting with AT
1
R-ECII. However, other unknown
pathological mechanisms of AT1-AA action need to be
further explored. Obtaining AT1-AA is the primary goal in
establishing AT1-AA-positive animal model and studying the
pathological significance of and mechanisms underlying this
antibody in diseases such as preeclampsia [15]. Currently,
isolating antibody from the sera of preeclamptic patients is
a basic approach to obtaining AT1-AA; however, it is crucial
to acquire other sources of AT1-AA because of the limited
availability of clinical patients’ sera, collection difficulties,
and large losses when purification is not timely [16]. Active
immunization is an alternate method for obtaining AT1-AA,
which involve mixing synthetic AT
1
R-ECII with incomplete
Freund’s adjuvant to retrieve the antigen and injecting it into
the animals by subcutaneous injection with a booster injec-
tion administered at 2-week intervals. Typically, it is possible
to procure high titer until the 8th week [17]. Therefore, active
immunization requires a relatively long time and a large dose
of antigen peptides. In addition, the retrieved antibodies are
usually polyclonal in nature. Therefore, it is important to
obtain AT1-mAb with high potency and specificity to allow
the study of the pathologic roles of AT1-AA [18]. Monoclonal
antibody technology was used in the present experiment.
The synthetic peptide AT
1
R-ECII was used to actively immu-
nize Balb/C mice through subcutaneous injection, and then
single B lymphocytes capable of secreting AT1-mAb were
hybridized with unlimited proliferating myeloma cells to
obtain hybrid cells that could be immortalized and secrete
AT1-mAb. The hybridomas were selected using ELISA, and
AT1-mAbwas extracted frommouse ascites after hybridomas
were inoculated into Balb/C mice for 2 weeks. Our results
showed that AT1-mAb can be extracted from hybridoma
supernatants and mouse ascites, the content of AT1-mAb
purified from mouse ascites was higher than that purified
from the hybridoma supernatant, and the AT1-mAb purified
from mouse ascites belongs to the IgG immunoglobulin
class. Additionally, compared to extracting AT1-mAb from
hybridoma supernatants, extracting AT1-mAb from mouse
ascites is of higher potency and less cost. Therefore, we chose
the mouse ascites method for preparing purified AT1-mAb.
Numerous studies have shown that there are a variety of
G-protein-coupled receptors, including AT
1
R, on the surface
of mouse vascular endothelial cells [19] and smooth muscle
cells [20], as well as on neonatal rat cardiomyocytes [21].
Ang II, an endogenous agonist of the AT
1
R, binds to AT
1
R
and causes a positive inotropic effect, such as the increased
beat frequency of cardiomyocytes and induction of vaso-
constriction [22]. Therefore, after the specificity of the AT1-
mAb purified from mouse ascites was confirmed, neonatal
rat cardiomyocyte experiments and isolated vascular ring
technology were used to evaluate the biological activity
of AT1-mAb. When AT1-mAb was added to the culture
medium of neonatal rat cardiomyocytes, the beat frequencies
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Figure 5: Elevated blood pressure of pregnant mice caused by AT1-mAb. (a) Control group; (b) AT1-mAb group; (c) content of AT1-mAb in
sera of mice; (d) systolic blood pressure levels in the pregnant mouse model. ∗𝑃 < 0.05 versus saline. Data represent the mean ± SEM; 𝑛 = 6.
of cardiomyocytes were significantly increased, similar to
the effect of AT1-AA isolated from patients’ sera. When the
AT
1
R blocker valsartan was added to the medium first, the
cell surface receptors were blocked by blocking the effect of
AT1-mAb on beat frequency in rat neonatal cardiomyocytes;
the AT
2
R blocker PD123319 did not have a blocking effect.
Furthermore, similar to AT1-AA purified from patients’ sera,
AT1-mAb purified from mouse ascites caused observable
vasoconstriction inmouse thoracic aorta. If the AT
1
Rblocker
valsartan was added prior to giving AT1-mAb treatment in
the isolated vascular ring, vasoconstriction was completely
blocked, whereas the AT
2
R blocker PD123319 did not block
the effect. All of the above observations demonstrate that
AT1-mAb purified frommouse ascites does not bind to AT
2
R
but rather specifically activates AT
1
R, thereby exerting its
agonist-like biological effects. In addition, compared to the
instantaneous vasoconstrictor effect caused by Ang II, AT1-
mAb and AT1-AA caused continued contraction in mouse
thoracic aorta, which suggests that activation of AT
1
R with-
out desensitizationmay be an importantmechanismwhereby
AT1-AA produces pathological and damaging effects. Addi-
tional studies are required to further explore this putative
mechanism.
Finally, to confirm that AT1-mAb plays a biological role
in vivo, we injected AT1-mAb into Balb/C mice via the tail
vein on the 13th day of gestation. Researchers demonstrated
that the half-life of clinically sourced AT1-AA is about 10
days, so that the AT1-AA can be retained in the body for
a long period, and thus mouse blood pressure may also be
maintained at a high level after AT1-AA injection [23]. In
addition, when pregnant mice were given an injection of
AT1-mAb purified from ascites, blood pressure on day 14
of gestation was increased and continued until the end of
the experiment. This suggests that AT1-mAb extracted from
ascites simulated patient-derived antibodies both in vitro and
in vivo.
In summary, we prepared AT1-mAb with high specificity,
high concentration, and biological activity by inoculating
hybridomas that secrete AT1-mAb into the mouse abdominal
cavity (Figure 6). Preparation of AT1-mAb is required to
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establish AT1-AA-positive animal models and will be a useful
tool for the research of clinical diseases that manifest a high
titer of AT1-AA, such as preeclampsia.
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